HC Andersen Capital Events 30/03: Meet the top management in Penneo, Impero, MapsPeople, Ascelia Pharma, Roblon & BioPorto
HC Andersen Capital is hosting digital events where you can meet and ask questions directly to the top management. It is free for all to attend.
SaaS Deep Dive - Outlook for 2023 and market drivers
We are hosting a virtual Software-as-a-Service (SaaS) deep dive event to shed light on the software outlook for 2023 and get management insights into underlying market drivers from software companies in different markets. We have invited the management from Impero (Compliance), MapsPeople (Digital Indoor Mapping), and Penneo (Digital Signature and KYC), who will present their view on the current market outlook within their markets.
Looking into the beginning of 2023, we have seen much macroeconomic uncertainty, which has prolonged or changed sales processes for many software companies. However, the ongoing digital transformation continues, and this deep dive event will look into different software markets based on underlying market drivers and trends.
The scene and topic will be presented by HC Andersen Capital analysts Michael Friis and Kasper Lihn, who will set the scene for the topic and discuss the recent and expected global market development in the software industry. You can also ask questions during the event.
Disclaimer: HC Andersen Capital receives payment from MapsPeople, Impero and Penneo for a DigitalIR/Corporate Visibility agreement./Kasper Lihn 15.09 PM 15 March 2023.
Thurday 30th of March - 09:30 - 11:30
Sign up via. link
Ascelia Pharma - Orviglance commercial opportunity and progress towards launch
Meet and ask questions to deputy CEO and CCO Julie Waras Brogren from Ascelia Pharma, who will dive into the market size and potential of Orviglance and go-to-market strategy.
Ascelia Pharma is a Swedish biotech company with a focus on orphan oncology treatments. They develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. Currently, Ascelia pharma has two pipeline products, namely Orviglance and Oncoral. Orviglance is a novel contrast agent for MR-Imaging developed to improve the detection and visualization of focal liver lesions (Including liver metastases – and primary tumors) in patients with reduced kidney function. Oncoral is a phase 2 study with an estimated completion date in 2024. Oncoral is a daily tablet with an established potent anti-tumor effect – even in difficult to treat cancers with the potential to offer better patient outcomes with improved safety following a daily tablet treatment compared to intravenous high-dose infusions at the hospital.
Disclaimer: HC Andersen Capital receives payment from Ascelia Pharma for a DigitalIR/Corporate Visibility agreement. /Claus Thestrup 12:51 PM – 03/22/2023.
Thurday 30th of March - kl. 09:30 - 10:00
Sign up via. link
__________________
This event is in danish
Roblon - Præsentation af Q1 kvartalsregnskabet 2022/2023
Torsdag den 30. marts kl. 14:00 - 14:30
Roblon var den 16. marts ude med sit regnskab for 1. kvartal 2022/23, der dækker perioden 1. november 2022 til 31. januar 2023.
Som selskabet indikerede i forbindelse med årsregnskabet for 2021/22 tilbage i december 2022 vil det nye regnskabsår 2022/23 være karakteriseret ved en blød start med et udfordret 1. kvartal 2022/23, men et tiltagende momentum i løbet af regnskabsåret.
Mød og stil spørgsmål til ledelsen, som vil gå kvartalsregnskabet 2022/2023 igennem til et virtuelt live event.
Disclaimer: HC Andersen Capital modtager betaling fra Roblon for en Digital IR/Corporate Visibility abonnementsaftale. /Rasmus Køjborg, CFA kl. 16.24 d. 16/3-2023
Torsdag den 30. marts kl. 14:00 - 14:30
Sign up via. link
_____________________
BioPorto - Presentation of annual report 2022
BioPorto releases its Annual Report on March 30th and on the same day the company participates in a digital event hosted by HC Andersen Capital where CEO Tony Paré and CFO Neil Goldman will present the report and highlights from 2022 followed by a Q&A session.
Disclaimer: HC Andersen Capital receives payment from BioPorto for a Digital IR/Corporate Visibility subscription agreement. /Claus Thestrup 09.30 23 March 2023. (Posted 9.12 24 March).
Thurday 30th of March - kl. 14:30 - 15:00
Sign up via. link
Disclaimer: HC Andersen Capital receives payment from the companies mentioned for a DigitalIR/Corporate Visibility agreement. The content is not buy or sell recommendations.
Mie Halse
Head of Digital and Events
mie@hcandersencapital.dk
+45 28746640
HC Andersen Capital digitizes the relationship between listed companies and investors. We work long-term for companies that want more visibility in the market. #DemocraticIR - HC Andersen Capital works to democratize access to the financial market.